EcoDrugPlus

Phospholipase A2

Ensembl ID : ENSSFOG00015030839
Gene Symbol: LOC108926741
2 Cross references
175 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSFOG00015014335
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSFOG00015029931
Gene Symbol: LOC108929587
3 Cross references
231 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSSFOG00015009090
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSSFOG00015015674
Gene Symbol: PLG
3 Cross references
256 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSFOG00015016201
Gene Symbol: PLAT
1 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSFOG00015001744
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSSFOG00015017537
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSSFOG00015014672
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSSFOG00015014375
Gene Symbol: PLK1
1 Cross references
188 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSSFOG00015020017
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSSFOG00015012443
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).